Miromatrix Announces Participation in Upcoming Gilmartin Emerging Growth Company Showcase
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the Gilmartin Emerging Growth Company Showcase on August 31, 2022, at 9:30 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical Inc. (NASDAQ: MIRO) announced its participation in the Gilmartin Emerging Growth Company Showcase on August 31, 2022, at 9:30 am ET. The event will feature a presentation from Miromatrix management, which can be accessed via a live and archived webcast. Miromatrix is focused on bioengineering fully transplantable human organs, primarily human livers and kidneys, using its proprietary perfusion technology platform to address the organ shortage crisis.
Positive
- Participation in the Gilmartin Emerging Growth Company Showcase could enhance visibility among investors.
- Focus on bioengineering transplantable organs addresses critical organ shortage.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the company will participate in the Gilmartin Emerging Growth Company Showcase on August 31st, 2022.
Miromatrix’s management is scheduled to present at the Gilmartin Emerging Growth Company Showcase on Wednesday, August 31st, 2022 at 9:30 am ET. Interested parties can access the live and archived webcast here.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact
press@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.